Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06706609

Classification of Adult-onset Diabetes in Five Subgroups in Pakistani Population

This study aims to classify adult-onset diabetes patients into distinct data-driven clusters, such as severe insulin-deficient, severe insulin-resistant, mild obesity-related, and mild age-related diabetes, based on clinical and biochemical characteristics. Using a cross-sectional design, data will be collected from individuals attending outpatient diabetes clinics at tertiary care hospitals in Pakistan. The study will analyze the distribution of metabolic and demographic characteristics within each cluster and assess subgroup-specific risks for diabetic complications. Additionally, the relationship between clustering variables and the risk of complications will be evaluated to enhance the understanding of diabetes heterogeneity and its impact on patient outcomes.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of both genders whose age of disease onset was older than 16 years
  • Patients newly diagnosed with or previously diagnosed with T2D
  • Able and willing to provide written informed consent and to comply with the study

Exclusion criteria

  • Patients with other medical comorbidities (not a complication of diabetes), such as malignancies.
  • Pregnancy

Treatment and study plan

Primary outcomes

  1. Classify patients into data-driven clusters (e.g., severe insulin-deficient, severe insulin-resistant, mild obesity-related and mild age-related diabetes).

    Time frame: At the time of clinic visit during enrollment

Secondary outcomes

  1. Analyze the distribution of metabolic and demographic characteristics within each cluster.

    Time frame: At the time of clinic visit during enrollment

  2. • Assess subgroup-specific risks for diabetic macrovascular complications such as CVD, Stroke/TIA, and microvascular complications such as nephropathy, retinopathy, peripheral and autonomic neuropathy

    Time frame: At the time of clinic visit during enrollment

  3. Evaluate the relationship between clustering variables and complications.

    Time frame: At the time of clinic visit during enrollment

Study contacts

Contact information is provided by the study sponsor or research team.

Dr Jahanzeb Kamal Khan, MBBS, MBA, CRCP, MCPS

CONTACT

[email protected]

+923201212945

Dr Shaheryar Hasan, MBBS, MBA

CONTACT

[email protected]

+923121260642

Sponsors and collaborators

Lead sponsor

Getz Pharma

Industry

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Nov 26, 2024
Registry last updated
Nov 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.